Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activation

被引:42
作者
Liu, HB
Hu, YS
Medcalf, RL
Simpson, RW
Dear, AE
机构
[1] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3181, Australia
[2] Monash Univ, Div Biotechnol, Eastern Clin Res Unit, Melbourne, Vic 3181, Australia
[3] Box Hill Hosp, Dept Endocrinol & Diabet, Melbourne, Vic 3128, Australia
关键词
tumour necrosis factor alpha; plasminogen activator inhibitor type-1; thiazolidinedione; peroxisome proliferator-activated receptor gamma;
D O I
10.1016/j.bbrc.2005.06.055
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Increased plasminogen activator inhibitor type I (PAI-1) levels are observed in endothelial cells stimulated by tumour necrosis factor alpha (TNF alpha). Thiazolidinediones (TZDs) may inhibit elevated endothelial cell PAI-1 accounting, in part, for the putative atheroprotective effects of TZDs. In an endothelial cell line, Rosiglitazone (RG) and Pioglitazone (PG) inhibited induction of PAI-1 by TNF alpha. The specific peroxisome proliferator-activated receptor gamma (PPAR gamma) inhibitor, SR-202, failed to modulate this effect. RG also inhibited the effect of TNF alpha on a reporter gene construct harbouring the proximal PAI-1 promoter and PAI-1 mRNA in cells cotransfected with a dominant-negative PPAR-gamma construct. RG and PG attenuated TNF alpha-mediated induction of trans-acting factor(s) Nur77/Nurr1 and binding of nuclear proteins (NP) to the cis-acting element (NBRE). SR-202 failed to modulate these effects. The observations suggest TZDs inhibit TNF alpha-mediated PAI-1 induction independent of inducible PPAR gamma activation and this may involve in the modulation of Nur77/Nurr1 expression and NP binding to the PAI-1 NBRE. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:30 / 37
页数:8
相关论文
共 42 条
[1]   On the role of c-Jun in the induction of PAI-1 gene expression by phorbol ester, serum, and IL-1α in HepG2 cells [J].
Arts, J ;
Grimbergen, J ;
Toet, K ;
Kooistra, T .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (01) :39-46
[2]   Transcriptional regulation of plasminogen activator inhibitor type I gene by insulin - Insights into the signaling pathway [J].
Banfi, C ;
Eriksson, P ;
Giandomenico, G ;
Mussoni, L ;
Sironi, L ;
Hamsten, A ;
Tremoli, E .
DIABETES, 2001, 50 (07) :1522-1530
[3]   Peroxisome proliferator-activated receptor gamma (PPARγ) activation and its consequences in humans [J].
Bar-Tana, J .
TOXICOLOGY LETTERS, 2001, 120 (1-3) :9-19
[4]   PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation [J].
Chawla, A ;
Barak, Y ;
Nagy, L ;
Liao, D ;
Tontonoz, P ;
Evans, RM .
NATURE MEDICINE, 2001, 7 (01) :48-52
[5]   Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells [J].
Chen, YQ ;
Su, M ;
Walia, RR ;
Hao, Q ;
Covington, JW ;
Vaughan, DE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (14) :8225-8231
[6]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[7]  
COCKERILL GW, 1994, LAB INVEST, V71, P497
[8]   Differential binding of cAMP-responsive-element(CRE)-binding protein-1 and activating transcription factor-2 to a CRE-like element in the human tissue-type plasminogen activator (t-PA) gene promoter correlates with opposite regulation of t-PA by phorbol ester in HT-1080 and HeLa cells [J].
Costa, M ;
Medcalf, RL .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 237 (03) :532-538
[9]   Transcriptional regulation of the tissue-type plasminogen-activator gene in human endothelial cells: identification of nuclear factors that recognise functional elements in the tissue-type plasminogen-activator gene promoter [J].
Costa, M ;
Shen, Y ;
Maurer, F ;
Medcalf, RL .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 258 (01) :123-131
[10]   Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene [J].
Dennler, S ;
Itoh, S ;
Vivien, D ;
ten Dijke, P ;
Huet, S ;
Gauthier, JM .
EMBO JOURNAL, 1998, 17 (11) :3091-3100